Ardelyx (ARDX) Cash & Equivalents (2013 - 2026)
Ardelyx posted quarterly Cash & Equivalents of $31.2 million for Q1 2026, up 1.3% year-on-year from $30.8 million in Q1 2025, and down 54.1% on a QoQ basis from $68.0 million in Q4 2025.
Ardelyx (ARDX) has 14 years of Cash & Equivalents data on file, last reported at $31.2 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Equivalents rose 1.3% year-over-year to $31.2 million; the trailing twelve-month figure through Mar 2026 stood at $31.2 million (up 1.3% YoY), and the FY2025 full-year result was $68.0 million, up 4.72% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $31.2 million, down from $68.0 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $96.1 million in Q4 2022 and bottomed at $21.5 million in Q4 2023.
- The 5-year median for Cash & Equivalents is $47.1 million (2022), against an average of $52.3 million.
- The widest annual swing landed in 2023, when Cash & Equivalents plunged 77.67%; it then surged 202.43% in 2024.
- A 5-year view of Cash & Equivalents shows it stood at $96.1 million in 2022, then slumped by 77.67% to $21.5 million in 2023, then soared by 202.43% to $64.9 million in 2024, then increased by 4.72% to $68.0 million in 2025, then sank by 54.1% to $31.2 million in 2026.
- The last three Cash & Equivalents figures came in at $31.2 million (Q1 2026), $68.0 million (Q4 2025), and $42.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Ardelyx | 1.48 Bn | 1.25 Bn | 89.66 Mn | 31.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.21 Mn |
| Dec 31, 2025 | 68.00 Mn |
| Sep 30, 2025 | 42.72 Mn |
| Jun 30, 2025 | 90.05 Mn |
| Mar 31, 2025 | 30.81 Mn |
| Dec 31, 2024 | 64.93 Mn |
| Sep 30, 2024 | 47.43 Mn |
| Jun 30, 2024 | 41.89 Mn |
| Mar 31, 2024 | 36.15 Mn |
| Dec 31, 2023 | 21.47 Mn |
| Sep 30, 2023 | 33.77 Mn |
| Jun 30, 2023 | 30.06 Mn |
| Mar 31, 2023 | 92.49 Mn |
| Dec 31, 2022 | 96.14 Mn |
| Sep 30, 2022 | 61.63 Mn |
| Jun 30, 2022 | 53.41 Mn |
| Mar 31, 2022 | 47.08 Mn |
| Dec 31, 2021 | 72.43 Mn |
| Sep 30, 2021 | 75.29 Mn |
| Jun 30, 2021 | 86.75 Mn |
| Mar 31, 2021 | 84.07 Mn |
| Dec 31, 2020 | 91.03 Mn |
| Sep 30, 2020 | 91.01 Mn |
| Jun 30, 2020 | 100.49 Mn |
| Mar 31, 2020 | 105.90 Mn |
| Dec 31, 2019 | 181.13 Mn |
| Sep 30, 2019 | 92.67 Mn |
| Jun 30, 2019 | 89.63 Mn |
| Mar 31, 2019 | 92.04 Mn |
| Dec 31, 2018 | 78.77 Mn |
| Sep 30, 2018 | 75.02 Mn |
| Jun 30, 2018 | 91.75 Mn |
| Mar 31, 2018 | 67.75 Mn |
| Dec 31, 2017 | 75.38 Mn |
| Sep 30, 2017 | 59.45 Mn |
| Jun 30, 2017 | 63.64 Mn |
| Mar 31, 2017 | 71.21 Mn |
| Dec 31, 2016 | 74.60 Mn |
| Sep 30, 2016 | 160.36 Mn |
| Jun 30, 2016 | 146.67 Mn |
| Mar 31, 2016 | 171.68 Mn |
| Dec 31, 2015 | 107.00 Mn |
| Sep 30, 2015 | 129.05 Mn |
| Jun 30, 2015 | 141.53 Mn |
| Mar 31, 2015 | 98.32 Mn |
| Dec 31, 2014 | 107.29 Mn |
| Sep 30, 2014 | 112.04 Mn |
| Jun 30, 2014 | 117.81 Mn |
| Mar 31, 2014 | 33.22 Mn |
| Dec 31, 2013 | 34.44 Mn |
| Sep 30, 2013 | 23.53 Mn |
| Jun 30, 2013 | 23.75 Mn |